Trusted Resources: News & Meetings
Latest announcements and gatherings
Europe Grants Orphan Drug Status to JR-441, ERT for Sanfilippo A
The European Commission has granted an orphan drug designation to JR-441, JCR Pharmaceuticals’ brain-penetrating experimental enzyme replacement therapy (ERT) for Sanfilippo syndrome type A, the company has announced. The designation is given to investigative therapies with the potential to be safe and effective for rare, life-threatening, or chronically debilitating conditions that have no approved treatments, or where the potential therapy is showing significant benefit over existing treatments.
It is meant to accelerate JR-441’s clinical development and review by providing regulatory support and financial benefits. It also provides a 10-year marketing exclusivity period in Europe upon regulatory approval, if granted. JCR is planning to launch a global clinical trial testing the therapy in the first half of 2023. Sanfilippo syndrome type A, also known as mucopolysaccharidosis type IIIA, is caused by the absence or reduced activity of the heparan N-sulfatase enzyme due to mutations in the SGSH gene.
BookmarkRelated Content
-
In Silico Analysis of Potential Off-Target Sites to Gene Editing for Mucopolysaccharidosis Type I Using the CRISPR/C...Mucopolysaccharidosis type I (MPS I) is ...
-
Mass General – Lysosomal Storage Disorders ProgramThe Lysosomal Storage Disorders Program ...
-
A Guide to Understanding MPS VI (Maroteaux-Lamy Syndrome)Mucopolysaccharidosis VI (MPS VI) is a v...
-
Long-Term Evolution of Mucopolysaccharidosis Type I in Twins Treated With Enzyme Replacement Therapy Plus Hematopoie...Mucopolysaccharidoses (MPSs) are a heter...
-
Natalia Gomez-Ospina, MD, PhDNatalia Gomez-Ospina is an Assistant Pro...
-
Gene Therapy for Neuronopathic Mucopolysaccharidoses: State of the ArtThe need for long-lasting and transforma...
-
Genome Editing in Mucopolysaccharidoses and MucolipidosesMucopolysaccharidoses (MPS) and mucolipi...
Powered by
